ストックスクリーナーアプリを入手
23.87
1.32%
0.31
アフターアワーズ：
23.87
前日終値:
$23.56
開ける：
$23.56
24時間の取引高:
231.13K
Relative Volume:
0.77
時価総額：
$777.72M
収益：
-
当期純損益:
$-29.59M
株価収益率:
-18.72
EPS:
-1.275
ネットキャッシュフロー:
$-18.35M
1週間 パフォーマンス:
+25.10%
1か月 パフォーマンス:
+23.61%
6か月 パフォーマンス:
+174.37%
1年 パフォーマンス:
+247.45%
1日の値動き範囲:
$23.34
$24.55
1週間の範囲:
$19.06
$24.55
52週間の値動き範囲:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
名前
Nuvectis Pharma Inc
セクター
電話
360-837-7232
住所
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
23.87 | 760.78M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-02 | 開始されました | Maxim Group | Buy |
| 2025-03-17 | 開始されました | Laidlaw | Buy |
| 2022-07-13 | 開始されました | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc (NVCT) 最新ニュース
Nuvectis Pharma Launches New $200 Million ATM Program - TipRanks
Nuvectis Pharma (Nasdaq: NVCT) sets at-the-market stock sales capacity - Stock Titan
Nuvectis Pharma (NASDAQ: NVCT) sets at-the-market share sales via Jefferies - Stock Titan
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate - Sahm
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why - Yahoo Finance
Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% HigherWhat's Next? - MarketBeat
Nuvectis Pharma (NVCT) Slips 1.4% to $18.96 as Shares Approach Key Support LevelALMA Signal - vinanet.vn
Behavioral Patterns of NVCT and Institutional Flows - Stock Traders Daily
NVCT Q2 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline ProgressesInvestor Earnings Call - vinanet.vn
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap UpWhat's Next? - MarketBeat
NVCT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued R&D InvestmentPre-Earnings Setup - vinanet.vn
Certain Stock Options of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Nuvectis Pharma (NVCT) Holds Near $18.88 as Shares Consolidate Between Support and ResistanceSupport Level Bounce - Vinanet
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline Amid Ongoing Clinical Development - vinanet.vn
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market Wi - The National Law Review
Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next - TipRanks
Soleus group (NVCT) discloses 1.65M-share, 5.1% Nuvectis Pharma stake - Stock Titan
HC Wainwright Boosts Earnings Estimates for Nuvectis Pharma - MarketBeat
(NVCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical Risks - TipRanks
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Down After Earnings Miss - MarketBeat
Nuvectis Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nuvectis Pharma, Inc. 2Q 2026: Net loss $(7.02)M, EPS $(0.30) — 10-Q Summary - TradingView
NVCT: Q2 2026 net loss widened to $7.0M; $106.3M raised in July extends cash runway for clinical development - TradingView
Nuvectis Pharma (NASDAQ: NVCT) boosts cash with $115M stock sale and new drug licenses - Stock Titan
Nuvectis Reports $7.0 Million Q2 Net Loss After Pipeline Deals - Quiver Quantitative
NVCT: Secured $115M financing, advanced late-stage pipeline, and reported higher R&D-driven net loss - tradingview.com
Nuvectis Pharma Reports Q2 2026 Results, Highlights In-Licensing of Ciprocopan and NXP200 and $115 Million Follow-On Offering - Quiver Quantitative
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
NVCT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Nuvectis Pharma (NVCT) Holds Mid-Range as Shares Tick Up 0.37%Float Adjusted Cap - dars.gov.et
NVCT Q1 2026 Earnings: Narrower Loss of $0.26 per Share Beats Estimates by 17.77% as Clinical-Stage Spending ContinuesEarnings Stability Report - vinanet.vn
Nuvectis Pharma (NVCT) Holds Steady Near Support as Biotech Sector Navigates VolatilityTime Weighted Price - dars.gov.et
Nuvectis Pharma (NVCT) Expected to Announce Earnings on Tuesday - MarketBeat
Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.530|Chg%:+0.220 - TradingKey
NVCT|Nuvectis Pharma Inc|Price:19.310|Chg%:-0.840 - TradingKey
Nuvectis Pharma Inc (NVCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvectis Pharma Inc (NVCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvectis Pharma Inc (NVCT) Cash Flow - TradingKey
Nuvectis Pharma Inc (NVCT) Income Statement - TradingKey
Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39 - Moomoo
China approves Nuvectis’ ciprocopan for blood disorder PNH - Investing.com UK
Nuvectis Pharma Inc (NVCT) 財務データ
収益
当期純利益
現金流量
EPS
Nuvectis Pharma Inc (NVCT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
0.00%
3.22%
大文字化:
|
ボリューム (24 時間):